Chaired by Nobel laureate Phillip A. Sharp, PhD, SU2C’s Scientific Advisory Committee is comprised of highly accomplished researchers, physicians and patient advocates.
Chaired by Nobel laureate Phillip A. Sharp, PhD, SU2C’s Scientific Advisory Committee is comprised of highly accomplished researchers, physicians and patient advocates.
Director, Sidney Kimmel Comprehensive
Cancer Center
Johns Hopkins University
Chief Scientific Officer
Irell & Manella Cancer Center
Director’s Distinquished Chair
Morgan & Helen Chu Director’s Chair
Beckman Research Institute
Professor, Integrative Translational Sciences
City of Hope
Professor Emeritus
Institute for Advanced Study and
Cancer Institute of New Jersey
Lisa K. Simmons Distinguished Chair in
Comprehensive Oncology
Director, UTSW Harold C. Simmons Cancer Center
Professor of Medicine
Associate Dean of Oncology Programs
Professor
Department of Hematology & Hematopoietic
Cell Transplantation
City of Hope
Senior Director of Proteomics and Institute
Scientist
Broad Institute
Emily Herrmann Chair in Cancer Research and
Director
Methodist Cancer Center at Houston Methodist
Hospital
Director, Susan F. Smith Center for Women’s
Cancers
Dana-Farber Cancer Institute
Division of Solid Tumor Oncology
Grayer Family Chair
Memorial Sloan Kettering Cancer Center
Associate Dean of Experimental Therapeutics
Baylor College of Medicine
Associate Director of Translational Research
Dan L Duncan Comprehensive Cancer Center
Liu (Liao) Family Professor of Bioengineering
Stanford University
President and CEO
Principal Investigator, Cancer Immunology and Virology
Richard and Susan Smith Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Co-Director, Center for immuno-Oncology
Clinical Director
Center for Cancer Research
National Cancer Institute
Senior Scientist
Peter and Shelagh Godsoe Chair in Radiation Medicine
Princess Margaret Cancer Centre
Landry Family Professor of Medicine
Harvard Medical School
Program Director, Cancer Early Detection and Diagnostics Clinic
Massachusetts General Cancer Center
George Fabyan Professor
of Comparative Pathology
Co-Director, Harvard Institute of
Translational Immunology
Co-Director, Evergrande Center for
Immunologic Diseases Harvard Medical School
Otto Krayer Professor
Department of Systems Biology
Head of the Harvard Program in Therapeutic
Sciences – HiTS
Harvard Medical School
Chief Medical Officer
Dana-Farber Cancer Institute/ Boston Children’s Cancer and Blood Disorders Center
Global Head of External Innovation
Janssen, Pharmaceutical Companies of Johnson & Johnson
Sidney Farber Professor of Medicine,
Harvard Medical School
Dana-Farber Cancer Institute
Chief, Laboratory of Genome Integrity
NIH Distinguished Investigator
Center for Cancer Research National
Cancer Institute
CEO of engineering Health (enHealth)
Robert A. Welch Professor and Executive Dean
School of Engineering Medicine
Texas A&M University and Houston Methodist
Hospital
Institute Professor
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Chief Scientific Officer
Irell & Manella Cancer Center
Director’s Distinquished Chair
Morgan & Helen Chu Director’s Chair
Beckman Research Institute
Professor, Integrative Translational Sciences
City of Hope
Professor and Research Division Chief,
Department of Family Medicine
and Community Health
Rutgers Robert Wood Johnson Medical School
Vice Chair for Research and Professor,
Department of Population and Public Health Sciences
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California
Deputy Director
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Associate Vice President Health Research
Chair, Department of Indigenous Health
School of Medicine and Health Sciences
University of North Dakota
SU2C’s scientists are the most capable, passionate and dedicated in their respective fields. This group of extraordinary individuals is constantly pushing towards progress, thus allowing for revolutionary discoveries. SU2C is supported by a team of more than 3,000 scientists from more than 210 prestigious medical and educational institutions that are united under one cause to end cancer as we know it.
Dream Teams, Research Teams, SU2C Convergence Teams, SU2C Catalyst® Teams, and through Innovative Research Grants.
Stand Up To Cancer conducts a highly involved review process to identify which of the top research proposals have the potential to make a significant impact in the cancer space. The American Association for Cancer Research is SU2C’s scientific partner and supports the review of grants it administers on behalf of SU2C. This review process is conducted in collaboration with SU2C’s Scientific Advisory Committee.
46
Array ( [0] => 8 )
Array ( [0] => 8 )
Array ( [0] => 8 )